Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: A retrospective analysis of a monoinstitutional series

Oncology

Volumn 76, Issue 6, 2009, Pages 405-412

  Welz, Hanna ^a   Pöttgen, Christoph ^a   Abu Jawad, Jehad ^a   Wierlemann, Arne ^a   Wittig, Andrea ^a   Stüben, Georg ^b   Budach, Volker ^c   Lehnerdt, Goetz ^a   Jahnke, Klaus ^a   Sack, Horst ^a   Stuschke, Martin ^a,d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

5 Fluorouracil; Accelerated radiotherapy; Concomitant chemotherapy; Head and neck cancer; Hyperfractionation; Mitomycin C

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; ANTINEOPLASTIC AGENT; MITOMYCIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; FRACTIONATION; HEAD AND NECK CARCINOMA; HUMAN; HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; PARENTERAL NUTRITION; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; AGED; CARCINOMA; CLINICAL TRIAL; HEAD AND NECK TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65449181208     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000215927     Document Type: Article

References (41)

1. Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, Lesaunier F, Benassi T, Lemanski C, Geoffrois L, Lusinchi A, Verrelle P, Bardet E, Julieron M, Wibault P, Luboinski M, Benhamou E: Phase III randomized trial of very accelerated radiation ther apy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006;24:2873-2878.
2. Cummings BJ, O'Sullivan B, Keane TJ, Pintilie M, Liu F, McLean M, Payne D, Waldron P, Warde P, Gullane P: A prospective randomized trial of hyperfractionated versus conventional once daily radiation for advanced squamous cell carcinomas of the larynx and pharynx - 5year results. Int J Radiat Oncol Biol Phys 2000;48:151.
3. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M: A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-136.
4. Dobrowsky W, Naude J: Continuous hyper-fractionated accelerated radiotherapy with/ without mitomycin C in head and neck cancers. Radiother Oncol 2000;57:119-124.
5. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat On col Biol Phys 2000;48:7-16.
6. Hliniak A, Gwiazdowska B, Szutkowski Z, Kraszewska E, Kukolowicz P, Jarzabski A, Sochacka B, Mazurkiewicz M, Paprota K, Oliskiewicz W, Zadrozna O, Milecki P, Ku-biak M, Czopkiewicz L, Jagas M, Gozdz S, Wieczorek A, Woytowicz A, Cisowska B, Magdziarz H, Nowakowski S, Kosniewski W, Laskosz I, Serafin A, Gradon E: A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1week shortening overall time. Radiother Oncol 2002;62:1-10.
7. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851randomized trial. Radiother Oncol 1997;44:111-121.
8. Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van Den Bogaert W, Danczak S, Bolla M, et al: Hyper-fractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.
9. Jackson SM, Weir LM, Hay JH, Tsang VH, Durham JS: A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;43:39-46.
10. Marcial VA, Pajak TF, Chang C, Tupchong L, Stetz J: Hyperfractionated photon radiation therapy in the treatment of advanced squa-mous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 1987;13:41-47.
11. Olmi P, Crispino S, Fa l lai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Pon-ticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S: Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy- a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003;55:78-92.
12. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6and 7randomised controlled trial. Lancet 2003;362:933-940.
13. Pinto LH, Canary PC, Araujo CM, Bacelar SC, Souhami L: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991;21:557-562.
14. Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A, Krawitz H, Hamilton C, Keller J, Tripcony L , Wa l ker Q: A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 2001;60:113-122.
15. Skladowski K, Maciejewski B, Golen M, Pilecki B, Przeorek W, Tarnawski R: Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer- report on 3-year tumour control and normal tissue toxicity. Radiother Oncol 2000;55:101-110.
16. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maitre A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-ana lysis. Lancet 2006;368:843-854.
17. Stuschke M, Thames HD: Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259-267.
18. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-955.
19. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Ja hn ke K, St ueb en G, Her rma n n T, B a mberg M, Wust P, Hinkelbein W, Wernecke KD: Hyperfractionated accelerated chemoradia-tion with concurrent fluorouracil-mitomy-cin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06Prospective Randomized Trial. J Clin Oncol 2005;23:1125-1135.
20. Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, Ezzat I: A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. J Egypt Natl Canc Inst 2005;17:85-92.
21. Haffty BG, Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, Rockwell S, Sartorelli AC, Fischer JJ: Chemotherapy as an adjunct to radiation in the treatment of squa-mous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Tria ls. J Clin Oncol 1997;15:268-276.
22. Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, Rockwell S, Sartorelli AC, Ross DA, Sasaki CT, Fischer JJ: Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 2005;61:119-128.
23. Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, Rockwell S, Sartorelli AC, Fischer JJ: Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989;17:3-9.
24. Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, Wahid I, Turkan S, Tatsuzaki H, Dinshaw KA, Overgaard J: Radiotherapy with or without mitomycin C in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol 2003;67:17-26.
25. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
26. Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thoni A, Ozsahin M, Bernier J, Topfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C: Concomitant cisplatin significantly improves locore-gional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22:4665-4673.
27. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-1464.
28. Semrau R, Mueller R P, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O, Kocher M, Eich HT, Dietz A, Flentje M, Rudat V, Volling P, Schroeder M, Eckel HE: Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;64:1308-1316.
29. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324.
30. Stuschke M, Budach V, Dinges S, Jahnke K, Budach W, Heselmann I, Unger A, Stuben G, Sack H: Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas (in German). Strahlenther Onkol 1994;170:689-699.
31. Allison PD: Survival Analysis with the SAS System: A Practical Guide. Cary, SAS Institute, 1995, p 292.
32. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CT-CAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
33. RTOG: Radiation Therapy Oncology Group RTOG 0129:A phase III trial of concurrent radiation and chemotherapy (followed by surgery for residual primary/N2-3nodal disease) for advanced head and neck carcinomas. www.rtog.org/members/protocols/h0129/h0129.Pdf.
34. Thames HD Jr, Peters LJ, Withers HR, Fletcher GH: Accelerated fractionation vs. hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys 1983;9:127-138.
35. Budach W, Paulsen F, Welz S, Classen J, Scheithauer H, Marini P, Belka C, Bamberg M: Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 2002;86:470-476.
36. Kennedy KA, Rockwell S, Sartorelli AC: Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 1980;40:2356-2360.
37. Hoogsteen IJ, Pop LA, Marres HA, Merkx MA, van den Hoogen FJ, van der Kogel AJ, Kaanders JH: Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2006;64:83-89.
38. Bud ach V, Geisma r D, Haa ke D, St u sch ke M, Baumann M, Budach W, Grabenbauer G, Wust P, Hinkelbein W, Wernecke KD: Hemoglobin is an independent prognostic factor in locally advanced head and neck cancer-three year results from a German Multicentre Trial (ARO 95/6). Int J Radiat Oncol Biol Phys 2001;51:183.
39. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortoch-aux J, Calais G: Final results of the 94-01French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
40. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM: Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2005;61:1087-1095.
41. Vaupel P, Mayer A, Hockel M: Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006;182:63-71.